Gifted Molecular Science
June 16, 2025
Company Presentation
Infectious Disease and Vaccines
Founded in 2023, Gifted Molecular Science is committed to developing innovative antiviral therapies with a novel mechanism of action to combat COVID-19. With $4.0M from a strategic investor and $1.5M in government research funding, we have launched preclinical studies exploring our cutting-edge therapeutic platform.
Our proprietary druggable-PNA directly targets the RNA genome, offering a breakthrough approach distinct from conventional antivirals. Unlike traditional ASOs, our molecule efficiently crosses the cell membrane and resists enzymatic degradation in vivo, addressing critical challenges of existing therapies.
We are currently advancing our lead candidate, GMS-007, through preclinical development as a potential COVID-19 treatment. This groundbreaking technology also shows promise for treating other RNA viruses, including Dengue, Zika, West Nile, RSV, HMPV, and Influenza.
.jpg)
Company HQ City:
Incheon
Company HQ State:
Incheon-jikhal-si
Company HQ Country:
Korea, Republic of
Year Founded:
2023
Lead Product in Development:
GMS-007, antiviral for COVID-19
CEO
Kim, Sung Chun
Year Founded
2023
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
one
When you expect your next catalyst update?
6 month
What is your next catalyst (value inflection) update?
1 year
Website
www.giftedms.com
Primary Speaker
.jpg)
)
)
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}